Clinical Study of Ulinastatin Combined with Xuebijing on Sepsis with Septic Shock

ZHANG Jun; QIU Ying

doi:10.14033/j.cnki.cfmr.2015.21.018

Abstract：Objective:To observe the clinical therapeutic efficiency of Ulinastatin combined with Xuebijing on sepsis with septic shock.Method:72 patients from January 2010 to January 2015 on sepsis with septic shock were included and randomly divided into the control group and Xuebijing combined with Ulinastatin group(the study group),with 36 cases in each group.The patients in the control group were treated according to the therapy guideline of severe sepsis with septic shock.The patients in the study group were received Xuebijing injection 50 ml intravenous drip every 12 hours a day and Ulinastatin 200 000 Units intravenous drip every 8 hours a day for 7days.Blood concentrations of TNF-α,IL-6,PCT,CRP were tested and compared.The application time of Norepinephrine,the amount of Norepinephrine,the time of mechanical ventilation and the mortality of the two groups were recorded and compared.Result:IL-6, TNF-α,PCT,CRP in the study group decreased significantly after the treatment.The application time of norepinephrine was significantly shorter than that in the control group.The amount of Norepinephrine was significantly less than that of the control group.The time of mechanical ventilation in the study group was shorter than that in the control group,mortality of the study group was lower than that of the control group(P<0.05).Conclusion:The treatment of Xuebijing combined with Ulinastatin significantly reduced inflammation,promoted the stability of hemodynamics,reduced mortality,and it is worthy for clinical promoting widely.